<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7D129DA2-C185-4D12-AEB3-9AAB8A63179E"><gtr:id>7D129DA2-C185-4D12-AEB3-9AAB8A63179E</gtr:id><gtr:name>Biocenter Oulu</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D887E45F-03B1-48F9-8090-09BFE2AC5A60"><gtr:id>D887E45F-03B1-48F9-8090-09BFE2AC5A60</gtr:id><gtr:name>Faculty of Natural Sciences</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Obstetrics and Gynaecology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/872D8701-44D2-4D3C-B113-A795FA40D61F"><gtr:id>872D8701-44D2-4D3C-B113-A795FA40D61F</gtr:id><gtr:name>University of Helsinki</gtr:name><gtr:address><gtr:line1>Siltavuorenpenger 20 C</gtr:line1><gtr:line4>Helsinki</gtr:line4><gtr:line5>FI-00170</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Finland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7D129DA2-C185-4D12-AEB3-9AAB8A63179E"><gtr:id>7D129DA2-C185-4D12-AEB3-9AAB8A63179E</gtr:id><gtr:name>Biocenter Oulu</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D887E45F-03B1-48F9-8090-09BFE2AC5A60"><gtr:id>D887E45F-03B1-48F9-8090-09BFE2AC5A60</gtr:id><gtr:name>Faculty of Natural Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4F704645-463D-4573-ADD8-B52D9CF5354B"><gtr:id>4F704645-463D-4573-ADD8-B52D9CF5354B</gtr:id><gtr:firstName>Carlo Fiore</gtr:firstName><gtr:surname>Viscomi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C5769926-CC08-4385-B7EA-8973E2C334F6"><gtr:id>C5769926-CC08-4385-B7EA-8973E2C334F6</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Child</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/642EF1AF-0239-48C2-A0D7-1E648882841F"><gtr:id>642EF1AF-0239-48C2-A0D7-1E648882841F</gtr:id><gtr:firstName>Katja</gtr:firstName><gtr:surname>Simon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EFC6BF18-2246-4283-97AD-D2594E7372A6"><gtr:id>EFC6BF18-2246-4283-97AD-D2594E7372A6</gtr:id><gtr:firstName>Suzannah</gtr:firstName><gtr:otherNames>Alice</gtr:otherNames><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/385632B9-30B7-46E1-A686-BB316D0DD9FD"><gtr:id>385632B9-30B7-46E1-A686-BB316D0DD9FD</gtr:id><gtr:firstName>Dagan</gtr:firstName><gtr:surname>Wells</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/51FCF53A-3F40-46D7-8B85-357BF51641CE"><gtr:id>51FCF53A-3F40-46D7-8B85-357BF51641CE</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Samuels</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/806E292E-71D4-449E-80EA-E44137F8B1C0"><gtr:id>806E292E-71D4-449E-80EA-E44137F8B1C0</gtr:id><gtr:firstName>Karl</gtr:firstName><gtr:surname>Morten</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/91681F06-FB0C-421D-A8E0-A8D14BDA464F"><gtr:id>91681F06-FB0C-421D-A8E0-A8D14BDA464F</gtr:id><gtr:firstName>Joanna</gtr:firstName><gtr:surname>Poulton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A5BAD8CD-C642-4527-904B-94FBB29C6658"><gtr:id>A5BAD8CD-C642-4527-904B-94FBB29C6658</gtr:id><gtr:firstName>Justin</gtr:firstName><gtr:surname>St John</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ010448%2F1"><gtr:id>577D01B1-8D5A-4084-A6AE-F49ADFAA6690</gtr:id><gtr:title>Investigating the biology of mitochondrial DNA disease transmission to enable affected families to have healthy children</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J010448/1</gtr:grantReference><gtr:abstractText>Mitochondria are critically important for generating the energy that is essential for life. Despite the importance of mitochondria, one in 400 people has a maternally-inherited mutation in mitochondrial DNA (mtDNA), the blue print for some vital mitochondrial components. While most women transmitting these mtDNA mutations will have children who only develop mild symptoms, such as deafness in old age, they may be severely affected. The mtDNA mutations can cause a range of illnesses, including deafness, blindness, diabetes, loss of skills, heart and liver failure and there are no curative treatments. 

Some centres are developing techniques for replacing disabled mitochondria with healthy ones. In this technique (so-called &amp;quot;nuclear transfer&amp;quot;), embryos of the couple at risk of having an affected child are generated in vitro. At an early stage, the nucleus that contains all of the genetic material apart from the mitochondria is removed from the egg (oocyte) and placed into a healthy egg or embryo from which the nucleus has been removed. The resulting embryo can then be placed in the mother's womb where it becomes a baby. While experiments on monkeys and mice suggest that such babies will probably be healthy, they have not been done in humans. Replacing the nucleus does not prevent development into a baby, but it causes damage that probably requires radical re-organisation of the cell. Because the embryo is already highly organised at this stage, such manipulations could have consequences later in life.

We aim to improve the genetic management of these diseases using less radical techniques. Current approaches are hampered by our poor understanding of the underlying mechanisms. MtDNA is inherited via the female line only. The chances that a woman carrying mtDNA mutations will pass them on to her child, and that child develops symptoms, are exceptionally difficult to predict. This is because both mutant and normal mtDNA are found in the same individual. The severity of the disease depends on the proportion of abnormal mtDNAs in particular cells of the body. However, this proportion varies from one generation to the next and cannot be predicted. The variability in the number of abnormal mtDNAs inherited is caused by an event known as the mitochondrial bottleneck which takes place in the female germline.

The biological processes that we plan to study determine the effectiveness of medical interventions. These treatments include preimplantation genetic diagnosis where eggs are fertilized in a test tube, tested, and low risk embryos selected to start a pregnancy. We will investigate existing cellular mechanisms that might be able to eliminate the unhealthy mitochondria, without such drastic interventions. In the long term we may determine whether nuclear transfer damages the cellular processes for maintaining healthy mitochondria. We may also develop less radical procedures, to generate embryos that have healthy mitochondria, without causing damage to the cell. Our ultimate aim is to enable affected families to have healthier children.</gtr:abstractText><gtr:technicalSummary>Either mitophagy (recycling of mitochondria) or clonal proliferation of mtDNA subpopulations may underlie the unpredictable transmission of mutant mtDNA. 

We propose that mtDNA turnover by mitophagy can be modulated to enhance purifying selection of normal mtDNA during early development. 

We will determine whether: 
1) mitochondrial function influences mtDNA content of: 
a) &amp;quot;spare&amp;quot; human preimplantation embryos becoming available from families with mtDNA disease undergoing in vitro fertilisation
b) mouse oocytes with impaired mitochondrial function

2) mtDNA synthesis occurs in:
a) mouse and human oocytes maturating in vitro
b) mouse and donated human preimplantation embryos 
using BrdU pulse labelling.

This may reveal any contribution of clonal proliferation of mtDNA to &amp;quot;purifying selection&amp;quot;

3) Modulators of mitochondrial recycling by mitophagy can be developed to enhance purifying selection. We will investigate and quantitate mitophagy in mouse pre-implantation embryos using transgenics with fluorescent organelles. We will cross mice with GFP targeted to LC3 in the autophagosomes against mice with DS-red targeted to mitochondria. Mitophagy is apparent by co-localisation of red and green signals in offspring (and this can be quantitated in cell lines using Imagestream, a technique combining flow cytometry and fluorescence microscopy, fig1). 

We will use this model to determine whether mitophagy:
a) occurs in mouse oocytes and pre-implantation embryos
b) can be driven by exogenous treatments
c) is exacerbated in mouse models expected to modulate mitophagy, such as OPA1 knock down (required for mitochondrial fusion). 

4) Purifying selection of wild type mtDNA in pluripotent cell cultures, heteroplasmic for pathogenic mtDNA mutants, can be driven by agents identified in (3). 

Ultimately we will use the mouse with fluorescent autophagosomes to investigate mitophagy in:
a) nuclear and cytoplasmic transfer
b) multiple disease model</gtr:technicalSummary><gtr:potentialImpactText>One in 400 Caucasians carries a pathogenic mitochondrial DNA (mtDNA) mutation. Nevertheless, prenatal diagnosis to prevent transmission is poorly developed, because the unique segregation patterns resulting from heteroplasmy (co-existing normal and mutant mtDNA) during development are not understood. Even pre-implantation genetic diagnosis, where low risk embryos are preferentially transferred to the uterus, is poorly developed for mtDNA disease.

Immediate beneficiaries from this research are therefore those who suffer from these conditions, their progeny, and those who treat them. Longer-term beneficiaries include: both public-sector and commercial providers of fertility treatments; policymakers and regulators (including specifically the HFEA and its successor), who will gain information on the clinical possibilities; charities in the area of infertility treatment and counselling; and the general public whose understanding of science will be enlarged.

How will they benefit from this research?

The research will impact on the nation's health and wealth as follows. Understanding the biological mechanisms of mtDNA transmission will improve both prenatal and preimplantation diagnostic techniques for mtDNA diseases. As well as informing genetic management our study may also enable us to develop a new strategy for reducing transmission risks. Indeed, we intend to determine whether the existing cellular mechanisms for mitochondrial quality control can be used to destroy mutant mtDNA and reduce the transmission risk. This may be a safer alternative to genetic manipulation of mtDNA mutant load, or may be usable in conjunction with pre-implantation diagnosis. Furthermore the research required to develop safe nuclear transfer requires very many donated human oocytes. If our work superceeded nuclear transfer, oocytes would become available for other purposes. For instance, donor oocytes provide a simple alternative to affected women who want to reduce their transmission risk by being the birth mother but not the genetic mother. Available oocytes may also be donated for developing stem cell therapies.

Through this project, we will increase understanding of early embryo development by determining whether mitophagy (autophagy that specifically recycles spent mitochondria) occurs during preimplantation development, is important and/or affects segregation of mtDNA mutant populations. As nutrient availability affects autophagy, mitophagy could be an important determinant of metabolic programming. This will promote transfer of new, translational technology from laboratory to bedside and relieve the pressure on the donor oocytes needed for other applications.

The mouse model with red mitochondria and green autophagic vacuoles will facilitate future studies of mitophagy. A mouse model with down-regulated mitophagy would allow future studies of (i) potential ways to influence the mitochondrial transmission (ii) developmental programming of diabetes risks.

Public engagement
The principal applicant (JP) has experience explaining research to the general public. In 2009 she organised, chaired and lectured at an information evening for Oxford mitochondrial patients. This was highly rated by families attending (&amp;quot;Relevant to my family&amp;quot; 85%, &amp;quot;Overall satisfaction&amp;quot; 91). Patient support organisations presented posters at this meeting, including a woman who had a healthy child as a result of oocyte sampling (she described her experiences in JP's article Poulton et al, BMJ 338, 345 (2009)). A similar event is scheduled for 2011 and then every 1-2 years. In 2010 JP organised and chaired an international workshop on mtDNA transmission, with the European Neuromuscular Centre, to which she invited a patient representative. He presented lay views to the participating scientists and ethicists, including his experience of counselling, pre-implantation genetic diagnosis and the birth of his healthy child.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-12-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>352128</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mitochondrial Biology Unit</gtr:department><gtr:description>Collaboration with Mitochondrial Biology Unit</gtr:description><gtr:id>A00E723B-9A0C-4581-B816-5365DB7CAE95</gtr:id><gtr:impact>We co-chaired an international workshop (163rd ENMC International Workshop: Nucleoid and nucleotide biology in syndromes of mitochondrial DNA depletion myopathy. 12-14 December 2008, Naarden, The Netherlands) resulting in 2 publications. Cross-ferlisation of ideas result in a PLOS-genetics paper in 2010 and a Nucleic Acids Research paper in 2009.</gtr:impact><gtr:partnerContribution>Ian has provided reagents advice and expertise for many years</gtr:partnerContribution><gtr:piContribution>I provide him with ideas and patient materials.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>Collaboration with Dr K Simon</gtr:description><gtr:id>0E406508-5106-4E97-AD7D-EE410266710A</gtr:id><gtr:impact>Submitted publications
Abstracts accepted for Biochemical Society meeting, Mitochondrial Dynamics meeting, EUROMIT</gtr:impact><gtr:partnerContribution>Access to ImageStream technology and Expertise
Wellcome Trust Funding</gtr:partnerContribution><gtr:piContribution>Research activity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Helsinki (Helsingin yliopisto)</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Institute of Biomedicine</gtr:department><gtr:description>Collaboration with Helsinki</gtr:description><gtr:id>C1859A32-B572-492B-B033-EB97FF7894E3</gtr:id><gtr:impact>ongoing research project</gtr:impact><gtr:partnerContribution>They sent cell lines from their mouse model</gtr:partnerContribution><gtr:piContribution>Cell lines have been shared with us</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Natural Sciences</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Mathematics</gtr:department><gtr:description>Mathematics of mitochondrial disease</gtr:description><gtr:id>B43827B7-967A-47E2-B364-80654618C0EC</gtr:id><gtr:impact>Papers in draft/submission</gtr:impact><gtr:partnerContribution>They do the mathematics on our dataset</gtr:partnerContribution><gtr:piContribution>We provide the biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biocenter Oulu</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:department>Department of Paediatric Neurology</gtr:department><gtr:description>Investigation of patients with mitochondrial disease</gtr:description><gtr:id>E19ABAF6-8A96-4B48-A187-182DD2D702CB</gtr:id><gtr:impact>Paper submitted to Epilepsia
Prospective study of POLG1 mutations presenting in children with intractable epilepsy-prevalence and clinical features
J Uusimaa, V Gowda, A McShane, C Smith, J Evans, A Shrier, M Narasimhan, A O'Rourke, Y Rajabally, F Cowan, C Fratter, J Poulton
Paper in draft for submission to J Med Genet
Benign Cytochrome Oxidase Deficiency or Reversible Infantile Respiratory Chain Deficiency: Evidence for genetic heterogeneity
Johanna Uusimaa, Heinz Jungbluth, G Crisponi, Lucy Feng, Massimo Zeviani, Imelda Hughes, Eileen Treacy, Jacqueline Birks, Caroline Sewry, Francesco Muntoni, and Joanna Poulton</gtr:impact><gtr:partnerContribution>JP flew to Oulu for collaborative meeting which enabled discussions with several other groups</gtr:partnerContribution><gtr:piContribution>JP collected the original cohort of patients, conceived the first proposal which was funded by The Sigrid Juselius Foundation, Finland (Co-applicant on Senior Research Fellowship for Dr J Uusimaa) 50,000 Eur and The Paediatric Foundation, Finlandand 20,000 Eur. JP and KM both co-authored the current application (Academy of Finland) on which both are collaborators.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Optometry and Vision Sciences</gtr:department><gtr:description>Collaboration with Prof M Votruba, Cardiff</gtr:description><gtr:id>AB93F2BE-A861-4B8B-8542-7505327317D5</gtr:id><gtr:impact>submitted a joint publication</gtr:impact><gtr:partnerContribution>Marcela has provided us with mice, we provide her with samples from our mouse models</gtr:partnerContribution><gtr:piContribution>We are drafting grant applications together and have</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited talk University of Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>49896916-8160-4B57-9F2A-DFA734849646</gtr:id><gtr:impact>Invited talk to 50 researchers

collaborations</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk, Czech Academy of Science, Prague</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CB7C7C57-364A-4D0E-A873-B020726FF198</gtr:id><gtr:impact>I gave an invited talk to scientists working on the basic science that directly impacts on our understanding of the diseases in my patients. This progressed our analysis of a group of 3 patients and increased their enthusiasm for and interaction with clinical problems. It increased their understanding of the cutting edge therapies available for these patients and progress made through this award.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented a Poster at the Biochemical Soc Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10CA2E71-400B-46A1-AAF9-5F515A65099F</gtr:id><gtr:impact>Poster presentation by Karl Morten at a Biochemical Society Meeting

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk, University of Tampere</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>94018F1E-E649-4940-9661-5FC09B1048A9</gtr:id><gtr:impact>50 people attended seminar

Ongoing collaboration</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BPNA</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>15B77056-5673-4849-84A7-0B3CE41A7B52</gtr:id><gtr:impact>Plenary talk

Increased patient referrals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2007,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk, University of Oulu, Finland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>55040B89-799B-4188-8018-1C1853EC3B4C</gtr:id><gtr:impact>20 people attended seminar

Ongoing collaboration</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited talk, University of Sheffield</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D676BED5-1005-498A-9A2C-13D551F8D3EC</gtr:id><gtr:impact>50 people attended seminar

Ongoing collaboration</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to give 2 talks to HFEA committees</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>426D26CE-E35E-4784-B485-898A6E8D3D70</gtr:id><gtr:impact>I suggested that HFEA should allow the Newcastle Mitochondrial research group working on nuclear transfer as a treatment for mitochondrial diseases should now be permitted to perform experiments on healthy single cell embryos rather than just abnormal ones.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HFEA Review of the effectiveness and safety of methods to avoid mitochondria disease</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>970B56EC-F1EE-41D5-B27E-8A36D8F017E5</gtr:id><gtr:impact>Invited to give evidence at Human Fertilisation and Embryology Authority (HFEA) review, which attracted international speakers (US and Netherlands). I was cited in the policy document arising from this.</gtr:impact><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.hfea.gov.uk/docs/2011-04-18_Mitochondria_review_-_final_report.PDF</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Submissions to the HFEA open consultation on new techniques to prevent transmission of serious mitochondrial disease</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EB25A6D6-DD2A-4BF3-A7D4-309B41825BCC</gtr:id><gtr:impact>Our collaborative paper (with Drs Joerg Burgstaller and Iain Johnston) on mitochondrial DNA segregation suggests that an additional restriction on the practice of mitochondrial donation for preventing mtDNA disease. We made a presentation to the review, suggesting that there should be an acceptably close mitochondrial genetic distance between donors of permitted embryos and of permitted eggs. When two mtDNA haplotypes are present in a cell (mtDNA heteroplasmy), it is usually assumed that segregation (the proliferation of one haplotype over another) is negligible and best explained by random drift. An intensively studied mouse model showing tissue-specific mtDNA segregation is currently seen as an exception to this assumption. However, existing studies of mtDNA dynamics have focused on laboratory mouse strains with very limited genetic diversity, thus ignoring the fact that genetic differences between haplotypes may lead to proliferative differences. We have data showing that in the mouse, segregation between two mtDNA haplotypes is the rule rather than the exception and strongly depends on the genetic distance. Segregation is much less when mitochondrial haplotypes are closely related than when they are diverse. The dataset on which this is based is substantially larger than in any previous such studies. Hence, the mtDNA of the permitted embryo might increase to disease-causing levels in later generations. We cannot exclude the possibility that there might be segregation to significant levels during development in foetuses developing from embryos generated by nuclear transfer. The risk would be substantially reduced by matching the mtDNA haplotype of donors.

These data were quoted in the HFEA report on the consultation.</gtr:impact><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://www.hfea.gov.uk/docs/Third_Mitochondrial_replacement_scientific_review.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Nuffield Council on Bioethics</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1A6584A6-AF68-48CC-8885-4C9DAF3CFEC8</gtr:id><gtr:impact>I was invited to comment on the utility of nuclear transfer for preventing mtDNA diseases at a consultation meeting at the House of Lords when the findings of the council were launched.</gtr:impact><gtr:type>Participation in a national consultation</gtr:type><gtr:url>http://www.hfea.gov.uk/docs/Mito-Annex_VIII-science_review_update.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Developing ImageStream (fluorescence mitoscopy combined with cytometry in a single platfrom) to quantify mitophagy</gtr:description><gtr:id>E0DEC6BF-0392-4766-A555-D3D20A0CB68F</gtr:id><gtr:impact>Successful grant application (Wellcome) and oral presentation at Biochemical Society meeting</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Developing ImageStream to quantify mitophagy</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>INCell 1000 being used to quantify transient low frequency events</gtr:description><gtr:id>72027CD8-3F06-43B3-BDDF-A76A38ED4FF5</gtr:id><gtr:impact>Paper under review Human Molecular Genetics</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Developed high throughput imaging for detecting mitophagy</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Mice with fluorescent organelles for investigating mitophagy</gtr:description><gtr:id>55819A60-7677-4FC0-8F5F-2B23FEC162CA</gtr:id><gtr:impact>Liver stem cells with fluorescent organelles</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RedMIT/GFP-LC3 mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7A1DB7FA-F7BD-4BF5-8A79-38F12DB48ED0"><gtr:id>7A1DB7FA-F7BD-4BF5-8A79-38F12DB48ED0</gtr:id><gtr:title>Clinical features of the pathogenic m.5540G&amp;gt;A mitochondrial transfer RNA tryptophan gene mutation.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4767d613694b160a2224099a0d07c0e9"><gtr:id>4767d613694b160a2224099a0d07c0e9</gtr:id><gtr:otherNames>Ng YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B3C8AB4-C109-4CF8-ADF2-A69CEE87AD35"><gtr:id>9B3C8AB4-C109-4CF8-ADF2-A69CEE87AD35</gtr:id><gtr:title>Resistance of Dynamin-related Protein 1 Oligomers to Disassembly Impairs Mitophagy, Resulting in Myocardial Inflammation and Heart Failure.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5bceacc902e03fc9365d87fa48311369"><gtr:id>5bceacc902e03fc9365d87fa48311369</gtr:id><gtr:otherNames>Cahill TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C8ACF63D-34CD-4A5D-89FA-754E3303FC53"><gtr:id>C8ACF63D-34CD-4A5D-89FA-754E3303FC53</gtr:id><gtr:title>Mitochondrial DNA disease and developmental implications for reproductive strategies.</gtr:title><gtr:parentPublicationTitle>Molecular human reproduction</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/204a3a7e8b347f441d8fbaf7e6b21bf2"><gtr:id>204a3a7e8b347f441d8fbaf7e6b21bf2</gtr:id><gtr:otherNames>Burgstaller JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1360-9947</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B37CAE85-C1CD-46C4-AA1B-224EC5E1EBDC"><gtr:id>B37CAE85-C1CD-46C4-AA1B-224EC5E1EBDC</gtr:id><gtr:title>Mitophagy plays a central role in mitochondrial ageing.</gtr:title><gtr:parentPublicationTitle>Mammalian genome : official journal of the International Mammalian Genome Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eca250054e9974b10d22463fb5964e2e"><gtr:id>eca250054e9974b10d22463fb5964e2e</gtr:id><gtr:otherNames>Diot A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0938-8990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/889F90AF-59DA-44DE-ADFB-F694ACEB0446"><gtr:id>889F90AF-59DA-44DE-ADFB-F694ACEB0446</gtr:id><gtr:title>Is Placental Mitochondrial Function a Regulator that Matches Fetal and Placental Growth to Maternal Nutrient Intake in the Mouse?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a1b548c7be9d8e2dbb49a9dfa42719d"><gtr:id>0a1b548c7be9d8e2dbb49a9dfa42719d</gtr:id><gtr:otherNames>Chiaratti MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D458DF44-605C-445E-8CAA-E033A754E3E8"><gtr:id>D458DF44-605C-445E-8CAA-E033A754E3E8</gtr:id><gtr:title>Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e2b35510da18c4d24ede0199ba63a6c"><gtr:id>4e2b35510da18c4d24ede0199ba63a6c</gtr:id><gtr:otherNames>Liao C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A26376AD-8F06-4E13-8376-0D4D7BB5193D"><gtr:id>A26376AD-8F06-4E13-8376-0D4D7BB5193D</gtr:id><gtr:title>Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cffc962b932447a7204bc4603ea0b0cd"><gtr:id>cffc962b932447a7204bc4603ea0b0cd</gtr:id><gtr:otherNames>Uusimaa J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B491F04-E8F2-43FD-8EF3-921C8C14141D"><gtr:id>0B491F04-E8F2-43FD-8EF3-921C8C14141D</gtr:id><gtr:title>Modulating mitochondrial quality in disease transmission: towards enabling mitochondrial DNA disease carriers to have healthy children.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eca250054e9974b10d22463fb5964e2e"><gtr:id>eca250054e9974b10d22463fb5964e2e</gtr:id><gtr:otherNames>Diot A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A98DF70B-822C-4A30-8F8C-094B79E6C9A7"><gtr:id>A98DF70B-822C-4A30-8F8C-094B79E6C9A7</gtr:id><gtr:title>Mitochondrial content is central to nuclear gene expression: Profound implications for human health.</gtr:title><gtr:parentPublicationTitle>BioEssays : news and reviews in molecular, cellular and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/012cafc63e9859d9b11024ab4cb89e52"><gtr:id>012cafc63e9859d9b11024ab4cb89e52</gtr:id><gtr:otherNames>Muir R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0265-9247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C383279B-6E0B-4407-9F1A-F62946A06D1C"><gtr:id>C383279B-6E0B-4407-9F1A-F62946A06D1C</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E49E443-74BB-4E6A-8309-BAA4D7883BFB"><gtr:id>1E49E443-74BB-4E6A-8309-BAA4D7883BFB</gtr:id><gtr:title>Modulating mitochondrial quality in disease transmission: towards enabling mitochondrial DNA disease carriers to have healthy children.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eca250054e9974b10d22463fb5964e2e"><gtr:id>eca250054e9974b10d22463fb5964e2e</gtr:id><gtr:otherNames>Diot A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/38343850-A653-4423-8345-BBC54B88A1F5"><gtr:id>38343850-A653-4423-8345-BBC54B88A1F5</gtr:id><gtr:title>A novel quantitative assay of mitophagy: Combining high content fluorescence microscopy and mitochondrial DNA load to quantify mitophagy and identify novel pharmacological tools against pathogenic heteroplasmic mtDNA.</gtr:title><gtr:parentPublicationTitle>Pharmacological research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eca250054e9974b10d22463fb5964e2e"><gtr:id>eca250054e9974b10d22463fb5964e2e</gtr:id><gtr:otherNames>Diot A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1043-6618</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C6209F7-6061-4E3E-A642-6D730CB8945B"><gtr:id>4C6209F7-6061-4E3E-A642-6D730CB8945B</gtr:id><gtr:title>Stochastic modelling, Bayesian inference, and new in vivo measurements elucidate the debated mtDNA bottleneck mechanism.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73e2a8ea6b79ba02b89aab08ad7a1ad7"><gtr:id>73e2a8ea6b79ba02b89aab08ad7a1ad7</gtr:id><gtr:otherNames>Johnston IG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J010448/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>